<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34769512</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>21</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>08</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Senolytics: A Novel Strategy for Neuroprotection in ALS?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">12078</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms222112078</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive motor neurodegenerative disease that currently has no cure and has few effective treatments. On a cellular level, ALS manifests through significant changes in the proper function of astrocytes, microglia, motor neurons, and other central nervous system (CNS) cells, leading to excess neuroinflammation and neurodegeneration. Damage to the upper and lower motor neurons results in neural and muscular dysfunction, leading to death most often due to respiratory paralysis. A new therapeutic strategy is targeting glial cells affected by senescence, which contribute to motor neuron degeneration. Whilst this new therapeutic approach holds much promise, it is yet to be trialled in ALS-relevant preclinical models and needs to be designed carefully to ensure selectivity. This review summarizes the pathways involved in ALS-related senescence, as well as known senolytic agents and their mechanisms of action, all of which may inform strategies for ALS-focused drug discovery efforts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maximova</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9726-1076</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2008, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werry</LastName><ForeName>Eryn L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2008, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Science, The University of Sydney, Sydney, NSW 2008, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassiou</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Science, The University of Sydney, Sydney, NSW 2008, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>APP1132524</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant><Grant><GrantID>APP1154692</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000089322">Senotherapeutics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000089322" MajorTopicYN="N">Senotherapeutics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">senescence</Keyword><Keyword MajorTopicYN="N">senolytics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>13</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34769512</ArticleId><ArticleId IdType="pmc">PMC8584291</ArticleId><ArticleId IdType="doi">10.3390/ijms222112078</ArticleId><ArticleId IdType="pii">ijms222112078</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Logroscino G., Traynor B.J., Hardiman O., Chio A., Mitchell D., Swingler R.J., Millul A., Benn E., Beghi E. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry. 2010;81:385&#x2013;390. doi: 10.1136/jnnp.2009.183525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Campanari M.L., Bourefis A.R., Kabashi E. Diagnostic Challenge and Neuromuscular Junction Contribution to ALS Pathogenesis. Front. Neurol. 2019;10:68. doi: 10.3389/fneur.2019.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00068</ArticleId><ArticleId IdType="pmc">PMC6372519</ArticleId><ArticleId IdType="pubmed">30787905</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S.D., Weiss J.H. Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci. 2004;27:17&#x2013;23. doi: 10.1016/j.tins.2003.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2003.11.001</ArticleId><ArticleId IdType="pubmed">14698606</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S., Orrell R.W. Pathogenesis of amyotrophic lateral sclerosis. Br. Med. Bull. 2016;119:87&#x2013;98. doi: 10.1093/bmb/ldw026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bmb/ldw026</ArticleId><ArticleId IdType="pubmed">27450455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M., Brown R.H., Jr. Genetics of Amyotrophic Lateral Sclerosis. Cold Spring Harb. Perspect. Med. 2018;8:a024125. doi: 10.1101/cshperspect.a024125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024125</ArticleId><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J., Gonzalo I., Ruiz-Soto M., Berciano J. Why do motor neurons degenerate? Actualization in the pathogenesis of amyotrophic lateral sclerosis. Neurologia. 2019;34:27&#x2013;37. doi: 10.1016/j.nrl.2015.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nrl.2015.12.001</ArticleId><ArticleId IdType="pubmed">26853842</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W., Naniche N., Bogush A., Pedrini S., Trotti D., Pasinelli P. Small peptides against the mutant SOD1/Bcl-2 toxic mitochondrial complex restore mitochondrial function and cell viability in mutant SOD1-mediated ALS. J. Neurosci. 2013;33:11588&#x2013;11598. doi: 10.1523/JNEUROSCI.5385-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5385-12.2013</ArticleId><ArticleId IdType="pmc">PMC3724557</ArticleId><ArticleId IdType="pubmed">23843527</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz M.P. Nuedexta for the treatment of pseudobulbar affect: A condition of involuntary crying or laughing. Pharm. Ther. 2013;38:325&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3737988</ArticleId><ArticleId IdType="pubmed">23946627</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Jorgenson J.A., Newhouse B.J., Shefner J.M., Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: Efficacy and access to therapy&#x2014;A roundtable discussion. Am. J. Manag. Care. 2018;24:S175&#x2013;S186.</Citation><ArticleIdList><ArticleId IdType="pubmed">29693363</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira S.M., Ribeiro R., Logarinho E. Approaches towards Longevity: Reprogramming, Senolysis, and Improved Mitotic Competence as Anti-Aging Therapies. Int. J. Mol. Sci. 2019;20:938. doi: 10.3390/ijms20040938.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20040938</ArticleId><ArticleId IdType="pmc">PMC6413205</ArticleId><ArticleId IdType="pubmed">30795536</ArticleId></ArticleIdList></Reference><Reference><Citation>von Kobbe C. Targeting senescent cells: Approaches, opportunities, challenges. Aging. 2019;11:12844&#x2013;12861. doi: 10.18632/aging.102557.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.102557</ArticleId><ArticleId IdType="pmc">PMC6949083</ArticleId><ArticleId IdType="pubmed">31789602</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng Y.Q., Guan J.T., Xu X.H., Fu Y.C. Senescence-associated beta-galactosidase activity expression in aging hippocampal neurons. Biochem. Biophys. Res. Commun. 2010;396:866&#x2013;869. doi: 10.1016/j.bbrc.2010.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2010.05.011</ArticleId><ArticleId IdType="pubmed">20457127</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimri G.P., Lee X.H., Basile G., Acosta M., Scott C., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereirasmith O., et al. A Biomarker That Identifies Senescent Human-Cells in Culture and in Aging Skin In-Vivo. Proc. Natl. Acad. Sci. USA. 1995;92:9363&#x2013;9367. doi: 10.1073/pnas.92.20.9363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.20.9363</ArticleId><ArticleId IdType="pmc">PMC40985</ArticleId><ArticleId IdType="pubmed">7568133</ArticleId></ArticleIdList></Reference><Reference><Citation>Das M.M., Svendsen C.N. Astrocytes show reduced support of motor neurons with aging that is accelerated in a rodent model of ALS. Neurobiol. Aging. 2015;36:1130&#x2013;1139. doi: 10.1016/j.neurobiolaging.2014.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.09.020</ArticleId><ArticleId IdType="pubmed">25443290</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E., Beilby P.R., Kovacs M., Ibarburu S., Varela V., Barreto-Nunez R., Bradford S.C., Beckman J.S., Barbeito L. Emergence of Microglia Bearing Senescence Markers During Paralysis Progression in a Rat Model of Inherited ALS. Front. Aging Neurosci. 2019;11:42. doi: 10.3389/fnagi.2019.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00042</ArticleId><ArticleId IdType="pmc">PMC6403180</ArticleId><ArticleId IdType="pubmed">30873018</ArticleId></ArticleIdList></Reference><Reference><Citation>Birger A., Ben-Dor I., Ottolenghi M., Turetsky T., Gil Y., Sweetat S., Perez L., Belzer V., Casden N., Steiner D., et al. Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity. EBioMedicine. 2019;50:274&#x2013;289. doi: 10.1016/j.ebiom.2019.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.11.026</ArticleId><ArticleId IdType="pmc">PMC6921360</ArticleId><ArticleId IdType="pubmed">31787569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Tchkonia T., Pirtskhalava T., Gower A.C., Ding H.S., Giorgadze N., Palmer A.K., Ikeno Y., Hubbard G.B., Lenburg M., et al. The Achilles&#x2019; heel of senescent cells: From transcriptome to senolytic drugs. Aging Cell. 2015;14:644&#x2013;658. doi: 10.1111/acel.12344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12344</ArticleId><ArticleId IdType="pmc">PMC4531078</ArticleId><ArticleId IdType="pubmed">25754370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tombor B., Rundell K., Oltvai Z.N. Bcl-2 promotes premature senescence induced by oncogenic Ras. Biochem. Biophys. Res. Commun. 2003;303:800&#x2013;807. doi: 10.1016/S0006-291X(03)00402-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(03)00402-9</ArticleId><ArticleId IdType="pubmed">12670482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanneau D., Brunet M., Frisan E., Solary E., Fontenay M., Garrido C. Heat shock proteins: Essential proteins for apoptosis regulation. J. Cell. Mol. Med. 2008;12:743&#x2013;761. doi: 10.1111/j.1582-4934.2008.00273.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00273.x</ArticleId><ArticleId IdType="pmc">PMC4401125</ArticleId><ArticleId IdType="pubmed">18266962</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 2000;275:10761&#x2013;10766. doi: 10.1074/jbc.275.15.10761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.15.10761</ArticleId><ArticleId IdType="pubmed">10753867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C., Thielen P., Fisher J., Pasinelli P., Brown R.H., Korsmeyer S., Glimcher L. The proapoptotic BCL-2 family member BIM mediates motoneuron loss in a model of amyotrophic lateral sclerosis. Cell Death Differ. 2007;14:1386&#x2013;1389. doi: 10.1038/sj.cdd.4402166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4402166</ArticleId><ArticleId IdType="pubmed">17510659</ArticleId></ArticleIdList></Reference><Reference><Citation>Peviani M., Cheroni C., Troglio F., Quarto M., Pelicci G., Bendotti C. Lack of changes in the PI3K/AKT survival pathway in the spinal cord motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 2007;34:592&#x2013;602. doi: 10.1016/j.mcn.2007.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2007.01.003</ArticleId><ArticleId IdType="pubmed">17303436</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704&#x2013;707. doi: 10.1038/366704a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/366704a0</ArticleId><ArticleId IdType="pubmed">8259215</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J.Y., Souroullas G.P., Diekman B.O., Krishnamurthy J., Hall B.M., Sorrentino J.A., Parker J.S., Sessions G.A., Gudkov A.V., Sharpless N.E. Cells exhibiting strong p16 (INK4a) promoter activation in vivo display features of senescence. Proc. Natl. Acad. Sci. USA. 2019;116:2603&#x2013;2611. doi: 10.1073/pnas.1818313116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1818313116</ArticleId><ArticleId IdType="pmc">PMC6377452</ArticleId><ArticleId IdType="pubmed">30683717</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez-Villasenor I., Garwood C.J., Heath P.R., Simpson J.E., Ince P.G., Wharton S.B. Expression of p16 and p21 in the frontal association cortex of ALS/MND brains suggests neuronal cell cycle dysregulation and astrocyte senescence in early stages of the disease. Neuropathol. Appl. Neurobiol. 2020;46:171&#x2013;185. doi: 10.1111/nan.12559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12559</ArticleId><ArticleId IdType="pmc">PMC7217199</ArticleId><ArticleId IdType="pubmed">31077599</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcorta D.A., Xiong Y., Phelps D., Hannon G., Beach D., Barrett J.C. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA. 1996;93:13742&#x2013;13747. doi: 10.1073/pnas.93.24.13742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.24.13742</ArticleId><ArticleId IdType="pmc">PMC19411</ArticleId><ArticleId IdType="pubmed">8943005</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol. Dis. 2000;7:613&#x2013;622. doi: 10.1006/nbdi.2000.0314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2000.0314</ArticleId><ArticleId IdType="pubmed">11114260</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison R.S., Kinoshita Y. The role of p53 in neuronal cell death. Cell Death Differ. 2000;7:868&#x2013;879. doi: 10.1038/sj.cdd.4400741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4400741</ArticleId><ArticleId IdType="pubmed">11279532</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimian A., Ahmadi Y., Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair. 2016;42:63&#x2013;71. doi: 10.1016/j.dnarep.2016.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2016.04.008</ArticleId><ArticleId IdType="pubmed">27156098</ArticleId></ArticleIdList></Reference><Reference><Citation>Demidenko Z.N., Korotchkina L.G., Gudkov A.V., Blagosklonny M.V. Paradoxical suppression of cellular senescence by p53. Proc. Natl. Acad. Sci. USA. 2010;107:9660&#x2013;9664. doi: 10.1073/pnas.1002298107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002298107</ArticleId><ArticleId IdType="pmc">PMC2906905</ArticleId><ArticleId IdType="pubmed">20457898</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund A., Orjalo A.V., Desprez P.Y., Campisi J. Inflammatory networks during cellular senescence: Causes and consequences. Trends Mol. Med. 2010;16:238&#x2013;246. doi: 10.1016/j.molmed.2010.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2010.03.003</ArticleId><ArticleId IdType="pmc">PMC2879478</ArticleId><ArticleId IdType="pubmed">20444648</ArticleId></ArticleIdList></Reference><Reference><Citation>Limbad C., Oron T.R., Alimirah F., Davalos A.R., Tracy T.E., Gan L., Desprez P.Y., Campisi J. Astrocyte senescence promotes glutamate toxicity in cortical neurons. PLoS ONE. 2020;15:e0227887. doi: 10.1371/journal.pone.0227887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0227887</ArticleId><ArticleId IdType="pmc">PMC6964973</ArticleId><ArticleId IdType="pubmed">31945125</ArticleId></ArticleIdList></Reference><Reference><Citation>Kia A., McAvoy K., Krishnamurthy K., Trotti D., Pasinelli P. Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha. Glia. 2018;66:1016&#x2013;1033. doi: 10.1002/glia.23298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23298</ArticleId><ArticleId IdType="pmc">PMC5873384</ArticleId><ArticleId IdType="pubmed">29380416</ArticleId></ArticleIdList></Reference><Reference><Citation>Michal I., Guy S., Itskovitz-Eldor J., Michel R. Astrocytes in Pathogenesis of ALS Disease and Potential Translation into Clinic. Astrocyte Physiol. Pathol. 2017;2018:93. doi: 10.5772/intechopen.72862.</Citation><ArticleIdList><ArticleId IdType="doi">10.5772/intechopen.72862</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan K.A., Weigel M.K., Adler D.I., Couthouis J., Liddelow S.A., Gitler A.D., Barres B.A. Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nat. Commun. 2020;11:3753. doi: 10.1038/s41467-020-17514-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17514-9</ArticleId><ArticleId IdType="pmc">PMC7385161</ArticleId><ArticleId IdType="pubmed">32719333</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K., Abdel-Moaty H., Hunter J., Mhatre M., Mou S., Nguyen K., Potapova T., Pye Q.N., Qi M., Rice H., et al. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J. Neuroinflamm. 2006;3:2. doi: 10.1186/1742-2094-3-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-2</ArticleId><ArticleId IdType="pmc">PMC1360663</ArticleId><ArticleId IdType="pubmed">16436205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Yang B., Zhang D. Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. Glia. 2011;59:946&#x2013;958. doi: 10.1002/glia.21167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21167</ArticleId><ArticleId IdType="pmc">PMC3077460</ArticleId><ArticleId IdType="pubmed">21446050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K., Fedynyshyn J., Ferrell S., Floyd R.A., Gordon B., Grammas P., Hamdheydari L., Mhatre M., Mou S., Pye Q.N., et al. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol. Dis. 2003;14:74&#x2013;80. doi: 10.1016/S0969-9961(03)00087-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-9961(03)00087-1</ArticleId><ArticleId IdType="pubmed">13678668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J., Smith A.J., Kuzmin-Nichols N., Zesiewicz T.A., Jahan I., Shytle R.D., Kim S.H., Sanberg C.D., Vu T.H., Gooch C.L., et al. Humoral factors in ALS patients during disease progression. J. Neuroinflamm. 2015;12:127. doi: 10.1186/s12974-015-0350-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0350-4</ArticleId><ArticleId IdType="pmc">PMC4487852</ArticleId><ArticleId IdType="pubmed">26126965</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R., Zecca C., Piccininni M., Benmahamed S., Dell&#x2019;Abate M.T., Barulli M.R., Capozzo R., Battista P., Logroscino G. Plasma Inflammatory Cytokines Are Elevated in ALS. Front. Neurol. 2020;11:552295. doi: 10.3389/fneur.2020.552295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.552295</ArticleId><ArticleId IdType="pmc">PMC7691268</ArticleId><ArticleId IdType="pubmed">33281700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohuslav J., Chen L.F., Kwon H., Mu Y., Greene W.C. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J. Biol. Chem. 2004;279:26115&#x2013;26125. doi: 10.1074/jbc.M313509200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M313509200</ArticleId><ArticleId IdType="pubmed">15073170</ArticleId></ArticleIdList></Reference><Reference><Citation>Buj R., Leon K.E., Anguelov M.A., Aird K.M. Suppression of p16 alleviates the senescence-associated secretory phenotype. Aging. 2021;13:3290&#x2013;3312. doi: 10.18632/aging.202640.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.202640</ArticleId><ArticleId IdType="pmc">PMC7906185</ArticleId><ArticleId IdType="pubmed">33550279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari R., Jat P. Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype. Front. Cell Dev. Biol. 2021;9:645593. doi: 10.3389/fcell.2021.645593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.645593</ArticleId><ArticleId IdType="pmc">PMC8039141</ArticleId><ArticleId IdType="pubmed">33855023</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivasubramanian M.K., Monteiro R., Balasubramanian P., Subramanian M. Oxidative Stress-Induced Senescence Alters Glutamate Transporter Expression in Human Brainstem Astrocytes. FASEB J. 2020;34:1. doi: 10.1096/fasebj.2020.34.s1.06566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.2020.34.s1.06566</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertusa M., Garcia-Matas S., Rodriguez-Farre E., Sanfeliu C., Cristofol R. Astrocytes aged in vitro show a decreased neuroprotective capacity. J. Neurochem. 2007;101:794&#x2013;805. doi: 10.1111/j.1471-4159.2006.04369.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04369.x</ArticleId><ArticleId IdType="pubmed">17250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Komine O. The multi-dimensional roles of astrocytes in ALS. Neurosci. Res. 2018;126:31&#x2013;38. doi: 10.1016/j.neures.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2017.09.011</ArticleId><ArticleId IdType="pubmed">29054467</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalloni A., Nutini M., Longone P. Role of the N-methyl-D-aspartate receptors complex in amyotrophic lateral sclerosis. Biochim. Biophys. Acta Mol. Basis Dis. 2013;1832:312&#x2013;322. doi: 10.1016/j.bbadis.2012.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2012.11.013</ArticleId><ArticleId IdType="pubmed">23200922</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Bogaert E., Dewil M., Hersmus N., Kiraly D., Scheveneels W., Bockx I., Braeken D., Verpoorten N., Verhoeven K., et al. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc. Natl. Acad. Sci. USA. 2007;104:14825&#x2013;14830. doi: 10.1073/pnas.0705046104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0705046104</ArticleId><ArticleId IdType="pmc">PMC1976195</ArticleId><ArticleId IdType="pubmed">17804792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussian T.J., Aziz A., Meyer C.F., Swenson B.L., van Deursen J.M., Baker D.J. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018;562:578&#x2013;582. doi: 10.1038/s41586-018-0543-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0543-y</ArticleId><ArticleId IdType="pmc">PMC6206507</ArticleId><ArticleId IdType="pubmed">30232451</ArticleId></ArticleIdList></Reference><Reference><Citation>Musi N., Valentine J.M., Sickora K.R., Baeuerle E., Thompson C.S., Shen Q., Orr M.E. Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell. 2018;17:e12840. doi: 10.1111/acel.12840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12840</ArticleId><ArticleId IdType="pmc">PMC6260915</ArticleId><ArticleId IdType="pubmed">30126037</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Kishimoto Y., Grammatikakis I., Gottimukkala K., Cutler R.G., Zhang S., Abdelmohsen K., Bohr V.A., Misra Sen J., Gorospe M., et al. Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer&#x2019;s disease model. Nat. Neurosci. 2019;22:719&#x2013;728. doi: 10.1038/s41593-019-0372-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0372-9</ArticleId><ArticleId IdType="pmc">PMC6605052</ArticleId><ArticleId IdType="pubmed">30936558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinta S.J., Woods G., Demaria M., Rane A., Zou Y., McQuade A., Rajagopalan S., Limbad C., Madden D.T., Campisi J., et al. Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson&#x2019;s Disease. Cell Rep. 2018;22:930&#x2013;940. doi: 10.1016/j.celrep.2017.12.092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.12.092</ArticleId><ArticleId IdType="pmc">PMC5806534</ArticleId><ArticleId IdType="pubmed">29386135</ArticleId></ArticleIdList></Reference><Reference><Citation>Acklin S., Zhang M., Du W., Zhao X., Plotkin M., Chang J., Campisi J., Zhou D., Xia F. Depletion of senescent-like neuronal cells alleviates cisplatin-induced peripheral neuropathy in mice. Sci. Rep. 2020;10:14170. doi: 10.1038/s41598-020-71042-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-71042-6</ArticleId><ArticleId IdType="pmc">PMC7447787</ArticleId><ArticleId IdType="pubmed">32843706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogrodnik M., Evans S.A., Fielder E., Victorelli S., Kruger P., Salmonowicz H., Weigand B.M., Patel A.D., Pirtskhalava T., Inman C.L., et al. Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice. Aging Cell. 2021;20:e13296. doi: 10.1111/acel.13296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13296</ArticleId><ArticleId IdType="pmc">PMC7884042</ArticleId><ArticleId IdType="pubmed">33470505</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker D.J., Childs B.G., Durik M., Wijers M.E., Sieben C.J., Zhong J., Saltness R.A., Jeganathan K.B., Verzosa G.C., Pezeshki A., et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016;530:184. doi: 10.1038/nature16932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature16932</ArticleId><ArticleId IdType="pmc">PMC4845101</ArticleId><ArticleId IdType="pubmed">26840489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogrodnik M., Zhu Y., Langhi L.G.P., Tchkonia T., Kruger P., Fielder E., Victorelli S., Ruswhandi R.A., Giorgadze N., Pirtskhalava T., et al. Obesity-Induced Cellular Senescence Drives Anxiety and Impairs Neurogenesis. Cell Metab. 2019;29:1233. doi: 10.1016/j.cmet.2019.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.01.013</ArticleId><ArticleId IdType="pmc">PMC6509279</ArticleId><ArticleId IdType="pubmed">31067450</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh Y.S., Kim S.H., Cho G.W. Functional Restoration of Amyotrophic Lateral Sclerosis Patient-Derived Mesenchymal Stromal Cells Through Inhibition of DNA Methyltransferase. Cell. Mol. Neurobiol. 2016;36:613&#x2013;620. doi: 10.1007/s10571-015-0242-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-015-0242-2</ArticleId><ArticleId IdType="pubmed">26210997</ArticleId></ArticleIdList></Reference><Reference><Citation>Granucci E.J., Griciuc A., Mueller K.A., Mills A.N., Le H., Dios A.M., McGinty D., Pereira J., Elmaleh D., Berry J.D., et al. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1(G93A) Mouse Model of amyotrophic lateral sclerosis. Sci. Rep. 2019;9:17728. doi: 10.1038/s41598-019-53982-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-53982-w</ArticleId><ArticleId IdType="pmc">PMC6881366</ArticleId><ArticleId IdType="pubmed">31776380</ArticleId></ArticleIdList></Reference><Reference><Citation>He S., Sharpless N.E. Senescence in Health and Disease. Cell. 2017;169:1000&#x2013;1011. doi: 10.1016/j.cell.2017.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.015</ArticleId><ArticleId IdType="pmc">PMC5643029</ArticleId><ArticleId IdType="pubmed">28575665</ArticleId></ArticleIdList></Reference><Reference><Citation>Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Jr., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215&#x2013;221. doi: 10.1038/356215a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/356215a0</ArticleId><ArticleId IdType="pubmed">1552940</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann-Stroissnigg H., Niedernhofer L.J., Robbins P.D. Hsp90 inhibitors as senolytic drugs to extend healthy aging. Cell Cycle. 2018;17:1048&#x2013;1055. doi: 10.1080/15384101.2018.1475828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2018.1475828</ArticleId><ArticleId IdType="pmc">PMC6110594</ArticleId><ArticleId IdType="pubmed">29886783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S., Fujita N., Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA. 2000;97:10832&#x2013;10837. doi: 10.1073/pnas.170276797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.170276797</ArticleId><ArticleId IdType="pmc">PMC27109</ArticleId><ArticleId IdType="pubmed">10995457</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokui K., Adachi H., Waza M., Katsuno M., Minamiyama M., Doi H., Tanaka K., Hamazaki J., Murata S., Tanaka F., et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet. 2009;18:898&#x2013;910. doi: 10.1093/hmg/ddn419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn419</ArticleId><ArticleId IdType="pubmed">19066230</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki D., Nakamura A., Hineno A., Kobayashi C., Kinoshita T., Yoshida K., Ikeda S. Elevation of serum heat-shock protein levels in amyotrophic lateral sclerosis. Neurol. Sci. 2016;37:1277&#x2013;1281. doi: 10.1007/s10072-016-2582-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-016-2582-1</ArticleId><ArticleId IdType="pubmed">27112486</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster C.P., Smith E.F., Shaw P.J., De Vos K.J. Protein Homeostasis in Amyotrophic Lateral Sclerosis: Therapeutic Opportunities? Front. Mol. Neurosci. 2017;10:123. doi: 10.3389/fnmol.2017.00123.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00123</ArticleId><ArticleId IdType="pmc">PMC5411428</ArticleId><ArticleId IdType="pubmed">28512398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L.T., Razzaq A., Di Gregorio S.E., Hong S., Charles B., Lopes M.H., Beraldo F., Prado V.F., Prado M.A.M., Duennwald M.L. Hsp90 and its co-chaperone Sti1 control TDP-43 misfolding and toxicity. FASEB J. 2021;35:e21594. doi: 10.1096/fj.202002645R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202002645R</ArticleId><ArticleId IdType="pubmed">33908654</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Gendron T.F., Xu Y.F., Ko L.W., Yen S.H., Petrucelli L. Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Mol. Neurodegener. 2010;5:33. doi: 10.1186/1750-1326-5-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-33</ArticleId><ArticleId IdType="pmc">PMC2941488</ArticleId><ArticleId IdType="pubmed">20804554</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K.M., Anderson N.G. The protein kinase B/Akt signaling pathway in human malignancy. Cell. Signal. 2002;14:381&#x2013;395. doi: 10.1016/S0898-6568(01)00271-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0898-6568(01)00271-6</ArticleId><ArticleId IdType="pubmed">11882383</ArticleId></ArticleIdList></Reference><Reference><Citation>Bent E.H., Gilbert L.A., Hemann M.T. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev. 2016;30:1811&#x2013;1821. doi: 10.1101/gad.284851.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.284851.116</ArticleId><ArticleId IdType="pmc">PMC5024680</ArticleId><ArticleId IdType="pubmed">27566778</ArticleId></ArticleIdList></Reference><Reference><Citation>Astle M.V., Hannan K.M., Ng P.Y., Lee R.S., George A.J., Hsu A.K., Haupt Y., Hannan R.D., Pearson R.B. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: Implications for targeting mTOR during malignancy. Oncogene. 2012;31:1949&#x2013;1962. doi: 10.1038/onc.2011.394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2011.394</ArticleId><ArticleId IdType="pmc">PMC3325598</ArticleId><ArticleId IdType="pubmed">21909130</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan P., Wang Y.J., Li S., Wang Y., He J.Y., Chen Y.Y., Deng H.Q., Huang W., Zhan J.K., Liu Y.S. The PI3K/Akt/mTOR pathway regulates the replicative senescence of human VSMCs. Mol. Cell. Biochem. 2016;422:1&#x2013;10. doi: 10.1007/s11010-016-2796-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-016-2796-9</ArticleId><ArticleId IdType="pubmed">27619662</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava S., Somasagara R.R., Hegde M., Nishana M., Tadi S.K., Srivastava M., Choudhary B., Raghavan S.C. Quercetin, a Natural Flavonoid Interacts with DNA, Arrests Cell Cycle and Causes Tumor Regression by Activating Mitochondrial Pathway of Apoptosis. Sci Rep. 2016;6:1&#x2013;13. doi: 10.1038/srep24049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24049</ArticleId><ArticleId IdType="pmc">PMC4828642</ArticleId><ArticleId IdType="pubmed">27068577</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Zhang Y., Liu A., Wang J., Li L., Chen X., Gao X., Xue Y., Zhang X., Liu Y. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells. Int. J. Mol. Sci. 2016;17:531. doi: 10.3390/ijms17040531.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17040531</ArticleId><ArticleId IdType="pmc">PMC4848987</ArticleId><ArticleId IdType="pubmed">27070592</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabogal-Guaqueta A.M., Munoz-Manco J.I., Ramirez-Pineda J.R., Lamprea-Rodriguez M., Osorio E., Cardona-Gomez G.P. The flavonoid quercetin ameliorates Alzheimer&#x2019;s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer&#x2019;s disease model mice. Neuropharmacology. 2015;93:134&#x2013;145. doi: 10.1016/j.neuropharm.2015.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.01.027</ArticleId><ArticleId IdType="pmc">PMC4387064</ArticleId><ArticleId IdType="pubmed">25666032</ArticleId></ArticleIdList></Reference><Reference><Citation>Conchon M., Freitas C.M., Rego M.A., Braga Junior J.W. Dasatinib: Clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia. Rev. Bras. Hematol. Hemoter. 2011;33:131&#x2013;139. doi: 10.5581/1516-8484.20110034.</Citation><ArticleIdList><ArticleId IdType="doi">10.5581/1516-8484.20110034</ArticleId><ArticleId IdType="pmc">PMC3520638</ArticleId><ArticleId IdType="pubmed">23284261</ArticleId></ArticleIdList></Reference><Reference><Citation>Han M.K., Barreto T.A., Martinez F.J., Comstock A.T., Sajjan U.S. Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. BMJ Open Respir. Res. 2020;7:e000392. doi: 10.1136/bmjresp-2018-000392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2018-000392</ArticleId><ArticleId IdType="pmc">PMC7047491</ArticleId><ArticleId IdType="pubmed">32071149</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X., Ren M., Jiang H., Cui S., Wang S., Jiang H., Qi Y., Wang J., Wang X., Dong G., et al. Downregulated AEG-1 together with inhibited PI3K/Akt pathway is associated with reduced viability of motor neurons in an ALS model. Mol. Cell. Neurosci. 2015;68:303&#x2013;313. doi: 10.1016/j.mcn.2015.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2015.08.009</ArticleId><ArticleId IdType="pubmed">26320681</ArticleId></ArticleIdList></Reference><Reference><Citation>Peviani M., Tortarolo M., Battaglia E., Piva R., Bendotti C. Specific induction of Akt3 in spinal cord motor neurons is neuroprotective in a mouse model of familial amyotrophic lateral sclerosis. Mol. Neurobiol. 2014;49:136&#x2013;148. doi: 10.1007/s12035-013-8507-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8507-6</ArticleId><ArticleId IdType="pubmed">23873136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Duan W., Wang W., Di W., Liu Y., Liu Y., Li Z., Hu H., Lin H., Cui C., et al. scAAV9-VEGF prolongs the survival of transgenic ALS mice by promoting activation of M2 microglia and the PI3K/Akt pathway. Brain Res. 2016;1648:1&#x2013;10. doi: 10.1016/j.brainres.2016.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.06.043</ArticleId><ArticleId IdType="pubmed">27392886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bureau G., Longpre F., Martinoli M.G. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J. Neurosci. Res. 2008;86:403&#x2013;410. doi: 10.1002/jnr.21503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21503</ArticleId><ArticleId IdType="pubmed">17929310</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V., Mishra M., Ghosh S., Tewari R., Basu A., Seth P., Sen E. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: Implications in neuroprotection. Brain Res. Bull. 2007;73:55&#x2013;63. doi: 10.1016/j.brainresbull.2007.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2007.01.016</ArticleId><ArticleId IdType="pubmed">17499637</ArticleId></ArticleIdList></Reference><Reference><Citation>Robaszkiewicz A., Balcerczyk A., Bartosz G. Antioxidative and prooxidative effects of quercetin on A549 cells. Cell Biol. Int. 2007;31:1245&#x2013;1250. doi: 10.1016/j.cellbi.2007.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellbi.2007.04.009</ArticleId><ArticleId IdType="pubmed">17583542</ArticleId></ArticleIdList></Reference><Reference><Citation>Das J., Chen P., Norris D., Padmanabha R., Lin J., Moquin R.V., Shen Z., Cook L.S., Doweyko A.M., Pitt S., et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 2006;49:6819&#x2013;6832. doi: 10.1021/jm060727j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm060727j</ArticleId><ArticleId IdType="pubmed">17154512</ArticleId></ArticleIdList></Reference><Reference><Citation>Suganthy N., Devi K.P., Nabavi S.F., Braidy N., Nabavi S.M. Bioactive effects of quercetin in the central nervous system: Focusing on the mechanisms of actions. Biomed. Pharmacother. 2016;84:892&#x2013;908. doi: 10.1016/j.biopha.2016.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2016.10.011</ArticleId><ArticleId IdType="pubmed">27756054</ArticleId></ArticleIdList></Reference><Reference><Citation>Porkka K., Koskenvesa P., Lundan T., Rimpilainen J., Mustjoki S., Smykla R., Wild R., Luo R., Arnan M., Brethon B., et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112:1005&#x2013;1012. doi: 10.1182/blood-2008-02-140665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-02-140665</ArticleId><ArticleId IdType="pubmed">18477770</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Trials.  [(accessed on 1 September 2021)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04063124.</Citation></Reference><Reference><Citation>Zhu Y., Tchkonia T., Fuhrmann-Stroissnigg H., Dai H.M., Ling Y.Y., Stout M.B., Pirtskhalava T., Giorgadze N., Johnson K.O., Giles C.B., et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15:428&#x2013;435. doi: 10.1111/acel.12445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12445</ArticleId><ArticleId IdType="pmc">PMC4854923</ArticleId><ArticleId IdType="pubmed">26711051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Doornebal E.J., Pirtskhalava T., Giorgadze N., Wentworth M., Fuhrmann-Stroissnigg H., Niedernhofer L.J., Robbins P.D., Tchkonia T., Kirkland J.L. New agents that target senescent cells: The flavone, fisetin, and the BCL-X-L inhibitors, A1331852 and A1155463. Aging. 2017;9:955&#x2013;963. doi: 10.18632/aging.101202.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101202</ArticleId><ArticleId IdType="pmc">PMC5391241</ArticleId><ArticleId IdType="pubmed">28273655</ArticleId></ArticleIdList></Reference><Reference><Citation>Anuar N.N.M., Hisam N.S.N., Liew S.L., Ugusman A. Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent. Front. Pharmacol. 2020;11:564108. doi: 10.3389/fphar.2020.564108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.564108</ArticleId><ArticleId IdType="pmc">PMC7768911</ArticleId><ArticleId IdType="pubmed">33381025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipps T.J., Eradat H., Grosicki S., Catalano J., Cosolo W., Dyagil I.S., Yalamanchili S., Chai A., Sahasranaman S., Punnoose E., et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk. Lymphoma. 2015;56:2826&#x2013;2833. doi: 10.3109/10428194.2015.1030638.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428194.2015.1030638</ArticleId><ArticleId IdType="pmc">PMC4643417</ArticleId><ArticleId IdType="pubmed">25797560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yosef R., Pilpel N., Tokarsky-Amiel R., Biran A., Ovadya Y., Cohen S., Vadai E., Dassa L., Shahar E., Condiotti R., et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 2016;7:11190. doi: 10.1038/ncomms11190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11190</ArticleId><ArticleId IdType="pmc">PMC4823827</ArticleId><ArticleId IdType="pubmed">27048913</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrini S., Sau D., Guareschi S., Bogush M., Brown R.H., Jr., Naniche N., Kia A., Trotti D., Pasinelli P. ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2. Hum. Mol. Genet. 2010;19:2974&#x2013;2986. doi: 10.1093/hmg/ddq202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq202</ArticleId><ArticleId IdType="pmc">PMC2901139</ArticleId><ArticleId IdType="pubmed">20460269</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>